Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ stem cell infusion (M.D. Anderson)
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ stem cell infusion is a specialized cell therapy utilized for patients experiencing graft failure or poor graft function following hematopoietic stem cell transplantation (SCT). This therapeutic approach involves the selection and concentration of CD34-positive hematopoietic stem and progenitor cells from a donor (often the original transplant donor) using an automated immunomagnetic selection system, such as the Miltenyi CliniMACS device. By infusing a concentrated dose of these progenitor cells, the treatment aims to boost and restore bone marrow function and blood cell production. The selection process typically depletes T-cells from the graft, which helps to reduce the risk of inducing or exacerbating graft-versus-host disease (GvHD) while providing the necessary cells for hematopoietic recovery. This specific program at M.D. Anderson Cancer Center provides compassionate access to this technology for patients with limited options after transplant failure.
- Other names
- CD34+ selected cellsCD34+ cell infusionCD34 positive stem cellsCD-34 positive stem cellsCD 34 positive stem cells
Beyond the preview
Go deeper on CD34+ stem cell infusion (M.D. Anderson).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ stem cell infusion (M.D. Anderson).